Atraverse Medical raises $29M to support FDA-approved heart tech
Atraverse Medical, a San Diego-based medtech startup, has raised $29 million in financing to help ramp up the commercialization of its Hotwire radiofrequency (RF) guidewire.
The Hotwire RF guidewire, which received U.S. Food and Drug Administration (FDA) approval in 2024, was designed to provide precise left-heart access to electrophysiologists while serving as a rail for catheter-based treatments. According to Atraverse, it offers “universal sheath compatibility,” allowing users to stick with the technology they prefer during RF procedures.
Hotwire has already been used in hundreds of heart procedures during its limited market release. With this latest round of funding secured—Atraverse previously raised $12.5 million in 2024—the company plans on expanding its commercialization efforts to cover all U.S. heart teams.
“This financing is a major milestone for Atraverse and underscores our evolution from a startup company to an emerging growth corporation,” John Slump, CEO/president and co-founder of Atraverse Medical, said in a statement. “We're scaling manufacturing, expanding our team, and investing in new product development to build on the Hotwire platform. Our investor syndicate includes angel investors, family offices, and medtech entrepreneurs who share our conviction that Hotwire is setting a new standard as the future of left-heart access.”
Hotwire image courtesy of Atraverse Medical.
“Hotwire delivers clinically significant advantages over existing left-heart access devices, and we are excited to be an early adopter and commercial customer,” added Vivek Y. Reddy, MD, director of cardiac arrhythmia services at Mount Sinai Hospital and a researcher familiar with the technology.
The team behind Atraverse are no strangers to this type of success. The company was founded in 2022 by the group that founded Farapulse, which was eventually acquired by Boston Scientific for an upfront payment of $295 million. The Farapulse technology is now one of Boston Scientific’s trademark offerings after receiving FDA approval in January 2024.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.